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Abstract. The anticancer drug paclitaxel was encapsulated into a bio-nanocomposite formed by magnetic nanoparticles,
chitosan and apatite. The aim of this drug carrier is to provide a new perspective against breast cancer. The dynamics of the pure
and encapsulated drug were investigated in order to verify possible molecular changes caused by the encapsulation, as well as to
follow which interactions may occur between paclitaxel and the composite. Fourier transformed infrared spectroscopy, thermal
analysis, inelastic and quasi-elastic neutron scattering experiments were performed. These very preliminary results suggest the
successful encapsulation of the drug.
1. Introduction
Paclitaxel (C47H51NO14, hereafter PTX) is an anticancer
drug whose effectiveness has been shown against different
kinds of tumors [1,2], including breast cancer [3], Fig. 1.
However, low water solubility and the fact that the drug
damages healthy cells still limit its clinical application [4].
These issues can be minimized by encapsulating PTX
into a bio-nanocomposite formed by a chitosan capsule
modified by apatite crystals. The latter shows great
affinity for breast cancer cells [5]. Additionally, by
placing magnetic nanoparticles in the core of this bio-
nanocomposite (hereafter bio-NCP) can allow for several
further applications [6–9].
The synthesis of the bio-NCP itself has been recently
reported [11]. Nevertheless, concerning the encapsulation,
a number of questions remain open. For instance, it is
well known that the PTX’s anti-cancer activity is driven
by its flexible structure [12–14], but the encapsulation can
induce severe dynamical changes and interactions between
the drug and the bio-NCP that may affect the releasing
process. This work is the very first attempt to shed light
into this particular problem.
To better understand the dynamics of pure and encap-
sulated PTX, Fourier transformed infrared spectroscopy
(FTIR), thermal analysis, as well as inelastic (INS) and
quasi-elastic neutron scattering (QENS) measurements
were carried out [15]. Our results suggest that the drug
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can be successfully encapsulated. It seems however that
the vibrations from the phenyl and acetyl groups are
constrained. The in-vivo implications of this observation
to the efficacy of this proposed drug carrier are out of the
scope of this paper.
2. Experimental section
2.1. Samples preparation
All chemicals used for the preparation of the samples were
purchased from Sigma-Aldrich.
The bio-NCP was prepared following the steps
described in [11], with magnetic nanoparticles presenting
the nominal formula Mn0.75 Zn0.25Fe1.70O4, synthesized in
a 0.1 M NaOH boiling solution, after a 120 min reaction.
In order to modify the chitosan surface with apatite the
mimetization process was used [11].
The encapsulation of PTX into the bio-NCP was
performed by the double emulsion method, which
allows for the inclusion of hydrophobic molecules into
hydrophilic systems, i.e. PTX into a chitosan capsule [4].
Hereafter, the sample containing the PTX encapsulated
into the bio-NCP will be referred as bio-NCP + PTX.
2.2. Details on the experimental techniques
PTX and bio-NCP + PTX structure was investigated by
X-ray powder diffraction (XPD) using the D10B-XPD
beamline at the Brazilian Synchrotron Light Laboratory
(LNLS, Brazil) using λ = 1.24 A˚.
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Figure 1. Schematic of the PTX molecule adapted from [10].
Circles highlight C-atoms cited along the text.
To evaluate the solid-state properties of PTX, bio-
NCP, bio-NCP + PTX and of pure chitosan Thermal
Gravimetric Analysis (TGA) and Differential Scanning
Calorimetry (DSC) measurements were performed using
a TG209 F1 Iris ASC, NETZSCH and a DSC (Q100)-TA
instrument, respectively. The measurements were carried
out between 120 K and 473 K.
The dynamics of PTX, bio-NCP + PTX and the
bio-NCP were further studied using FTIR, INS and
QENS. FTIR measurements were carried out at room
temperature between 400 and 4000 cm−1 using an ATR
Crystal (Bruker). INS data were collected at IN4 (ILL-
France) at 10 K with incident neutrons of about 17 meV
(λ = 2.2 A˚) and 68 meV (1.1 A˚). QENS and INS data were
obtained with an incident wavelength λ = 5 A˚ (3 meV,
E = 100 µeV) using the FOCUS spectrometer (PSI-
Switzerland). At FOCUS, PTX was measured at 100 K,
150 K, 200 K, 250 K and 300 K, while the bio-NCP and
bio-NCP + PTX at 100 K, 200 K and 300 K. The analysis
of the temperature dependence of the elastic intensity of
the PTX data allows for identifying relevant dynamical
transitions. For the neutron experiments, the samples were
mounted using the slab geometry inside of aluminum
containers with a calculated normal beam transmission
0.75. Vanadium runs were used to determine the resolution
function and to calibrate the detectors efficiency. To
analyze the data, the Bragg reflections were removed,
the QENS spectra were fitted using the 1D PAN: Peak
Analysis software [16] and the INS data were transformed
into the generalized density of vibrational states using
LAMP [17].
3. Results and discussion
3.1. Structural characterization
XPD pattern of PTX, Fig. 2a, shows two distinct
crystalline phases attributed to a dehydrated and a hydrated
form of the drug [19] with space groups P21212 and
P1211, respectively. After the encapsulation, due to the
loss of translation symmetry, only the ferrite and chitosan
reflections can be observed in the bio-NCP+ PTX pattern,
Fig. 2b.
(a) (b) 
Figure 2. XPD of PTX (a) and bio-NCP + PTX (b) obtained at
the LNLS using λ = 1.24 A˚. The PTX pattern shows the presence
of both hydrated and dehydrated semicrystalline forms, while in
the the bio-NCP patterns only the reflections associated to the
ferrite and chitosan are seen.
3.2. Thermal analysis
The DSC and TGA results between 300 and 473 K are
shown in Figs. 3a and b. An extended phase transition is
noted for PTX between 287 and 367 K accompanied by a
tiny mass loss, while a second endothermic phenomenon
is seen at 433 K. The first phase transition refers to a
partial dehydration of the compound inducing a structural
rearrangement, while the second refers to a solid-solid
transition [18]. These observations confirm that the
analyzed PTX sample is a mixture of hydrated and
dehydrated forms. For pure chitosan, Fig. 3a, an extended
phase transition observed between 370 and 470 K is related
to a water loss of about 3% [19], while in the bio-NCP and
bio-NCP + PTX this same transition is shifted to lower
temperatures, i.e. between 340 and 435 K and 310 K and
430 K, respectively. Due to confinement, the water loss
in these samples occurs in two steps. As shown in the
inset of Fig. 3a, in the bio-NCP the higher temperature
step involves more energy than observed in the bio-
NCP + PTX. We can hypothesize that this is caused by
a competition between the drug and the water molecules
for interacting with the chitosan’s NH and OH groups, thus
reducing the material’s hydration. To confirm this idea the
samples were investigated by FTIR, as described below.
In the DSC data collected at lower temperatures,
Fig. 3c, three subtle phase transitions centered at about
155, 205 and 235 K are noted for the PTX, while no
significant changes are observed for the other samples
(data are not presented). Although such changes are
very small in the DSC experiment, they might manifest
themselves in the neutron scattering experiments [20].
3.3. FTIR data analysis
Regarding the FTIR data, Fig. 4, all the PTX vibrational
peaks (black line) can be seen in the physical mixture
(green line), while in the bio-NCP + PTX (red line) a
considerable change in the spectra is noted. Furthermore,
as shown in the inset of Fig. 4, the PTX bands at
1703 cm−1 from the C = O ester stretching and at
1317 cm−1, assigned to the COO stretching [21] present in
bio-NCP + PTX confirm the presence of PTX in the
composite. Moreover, bending vibrations of NH groups
of chitosan, around 1563 cm−1, as well as the vibrations






Figure 3. DSC analysis of PTX, bio-NCP, bio-NCP + PTX and
pure chitosan between room temperature and 470 K (a). The inset
shows a comparison between the events in bio-NCP and bio-
NCP + PTX above 450 K. In (b), TGA shows the water loss in
the samples and (c) depicts the DSC analysis for PTX between
120 K and 300 K.
Figure 4. FTIR spectra for PTX (black), bio-NCP (blue), bio-
NCP + PTX (red) and physical mixture of bio-NCP and PTX
(green). The inset highlights the presence of PTX peaks in the
bio-NCP + PTX at 1317 cm−1 and 1703 cm−1.
around 1414 cm−1, [22] give rise to clear bands in the
bio-NCP + PTX. Both observations corroborate with the
DSC data, confirming the competition for interactions
between PTX and the chitosan’s NH and OH groups.
Additionally, the prominent peak at 1650 cm−1 related to
the C-N bonds, [23] is reduced in the bio-NCP + PTX.
Since such bonds are formed during the cross-linking
reaction and the formation of Schiff bases, which involve
the NH groups, the reduction of this peak further reinforces
the interaction of the drug with the chitosan.
3.4. Neutron scattering: QENS and vibrational
spectroscopy results
Now we turn to the analysis of the temperature dependence
of the low frequency spectra of pure PTX obtained on
FOCUS, Fig. 5a. In the INS data four main broad bands
centered at 80, 150, 103 and 250 cm−1 (the latter almost
out of the instrument limit) can be observed below 200 K.
Moreover, a clear change in the vibrational spectra is
seen in the same temperature region where the first phase
transition was observed in the DSC analysis. This change
(a) 
(b) 
Figure 5. INS (a) and QENS data (b) obtained at 300 K for
the pure PTX using FOCUS at the PSI. Above 100 K the data
for PTX was fitted with two Lorentzian functions and one flat
background. The inset depicts the QENS data obtained at selected
temperatures, where a QE signal is visible.
is also accompanied by the observation of a quasi-elastic
(QE) signal. To get insight on the activation energy of the
processes related to the QE signal the data was fitted using
a Dirac function and a sum of Lorentzians:
Sm(Q, ω)= [A0(Q)δ(ω)+ Ai (Q)i Li (iω)]⊗ R(ω)+ B
(1)
where Ai gives the structure factors, A0 is the elastic
incoherent structure factor, L i(iω) are the Lorentzian
functions (QE components), with a half-width at half-
maximum (HWHM) . R(ω) represents the experimental
resolution function (vanadium run) and B the background.
In order to get a better statistics the signal was summed
over the total Q-range. The data collected at 100 K could
then be fitted using a single Lorentzian, while for all
other temperatures an additional Lorentzian function was
necessary to correctly describe the data, see Fig. 5.
Figure 6a shows that the temperature dependence of
the integrated intensity under the elastic line for pure
PTX reduces ∼ 19% (see the inset) between 100 and
300 K, corresponding to the activation of ∼10 H in the
PTX molecule, or at least three CH3 groups. In addition,
the changes in the slope of the curve at 150 and 200 K
corroborate well with the phase transitions revealed by
the DSC data and the changes in the inelastic part
of the spectra. Therefore one can argue that the PTX
molecule indeed undergoes some dynamical transitions in
this temperature range. Figure 6b depicts the Arrhenius
02011-p.3
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Figure 6. (a) Temperature dependence of the elastic line for pure
PTX, shown in the inset for selected temperatures, integrated over
the energy resolution interval. (b) Temperature dependence of the
Full Width at Half Maximum (FWHM) of the QE signal observed
for pure PTX obtained using the fitting procedure described in the
text. The red lines indicate the Arrhenius model approximations.
The error bars in (a) are smaller than the experimental points.
plot of the variation of the full width at half maximum
(FWHM) for the drug molecule.
The relatively different values of the FWHM imply
that in the PTX molecules re-orientational motions occur
at a broad time scale. Using the Arrhenius law, activation
energies of 1.16 and 3.6 kJ/mol were obtained for the
first Lorentzian, and 6.11 kJ/mol, for the second one.
Assuming that the time scale of our QENS experiments
probes mainly the dynamics of methyl groups contained
in a harmonic potential with three-fold symmetry, it is
possible to crudely estimate the V3 potential barrier as
well as the first librational sub-state from the activation
energy of these re-orientational motions using simplified
numerical relations E0−1 (meV) = 0.47[V3(K)]0.548 and
Eact(K) = 0.598[V3(K)]1.05 [20]. If this assumption is
suitable, one would expect librational peaks around 64,
96 and 144 cm−1. Based on our ongoing DFT calculations
(private communication) [24], the two lower vibrations
are mainly attributed to the acetyl groups bonded to
C4 and C10 and the methyl group in C12, respectively
(Fig. 1), calculated at 66 and 96 cm−1. Differences between
the theoretical and experimental values as well as the
broadening in the observed peaks in Fig. 5a denote that
Figure 7. Normalized S(Q, ω) spectra of the bio-NCP and bio-
NCP+PTX at 300 K. The results for the fits of the QE signal are
also shown.
the methyl groups are not in a pure C3 symmetry. For the
lowest energy the side chain in C13 also plays an important
role. Considering the higher energy vibration, calculated
at 143 cm−1, a contribution from C20 in the oxetane ring
explains the broadening in the observed data.
Regarding the QENS spectra of the bio-NCP and
bio-NCP + PTX the data collected at 100 K and 200 K
could be described using a single Lorentzian and a flat
background function, while for fitting the bio-NCP +
PTX data collected at 300 K an additional Lorentzian
was necessary. No differences in the QE broadening
could be noted at 100 K and 200 K, suggesting the strong
confinement of the PTX inside the bio-NCP. However,
as in seen Fig. 7, a slight difference between the bio-
NCP and bio-NCP + PTX can be observed at 300 K,
thus allowing insight into the contribution from the drug
itself. A different background offset was needed due to
the increasing contribution of the Debye-Waller factor, and
for the additional Lorentzian a FWHM value of 0.72 meV
was obtained. Considering that this value is close to the
one found for the first Lorentzian used to fit the PTX data,
0.84 meV, we suggest that the extra QE signal observed in
the bio-NCP + PTX spectrum at 300 K might be assigned
to the drug. However, the validation of this idea needs
further studies.
Insight in the dynamics between 20 and 480 cm−1
was by analyzing the IN4 data. As shown in Fig. 8,
the band centered at 48 cm−1 in the PTX spectrum is
damped in the bio-NCP + PTX. In this region, the DFT
calculations show a great contribution from the PTX
phenyl rings and acetyl groups, which therefore seem
to be constrained by encapsulation. In addition, small
contributions around 110 cm−1 are noted in the difference
curve obtained by subtracting the bio-NCP + PTX signal
from that collected for the bio-NCP (green curve). Small
contributions in the difference curve are further noted in
the data collected using incident neutrons with 67.6 meV
energy around 280 cm−1, 330 cm−1 and above 400 cm−1.
Such contributions indicate that the encapsulated drug





Figure 8. INS spectra collected using IN4 at 10 K for PTX
(black circles), bio-NCP + PTX (red triangles) and bio-NCP
(blue squares). The green curve shows a difference between bio-
NCP + PTX and bio-NCP using incident energies of 17 (a) and
68 meV (b).
Conclusions and discussion
Typically thermal analysis methods are considered to
be the most suitable approaches for determination of
a successful encapsulation process. Normally, these
techniques are supplemented by FTIR to show that the
loss of the melting peak of the pure drug is due to its
complexation rather than thermal degradation or a loss of
crystallinity. Generally, the bands due to the complexed
part of the drug are shifted or have their intensities
altered. However as the mass of the encapsulated drug
does not exceed 5–15% of the complex, these alterations
are usually hidden, and only in some cases spectroscopic
changes indicating complex formation can be observed.
In addition, in the case of crystalline drugs such as PTX
studied in this paper, encapsulation leads to a disruption
of the intermolecular hydrogen bonding of the pure drug.
Consequently the Bragg reflections characteristic of the
isolated molecules are absent in the XPD patterns of the
encapsulated molecule, and only the Bragg reflections
characteristics of the encapsulation itself can be observed.
Owing to the same reason, intermolecular vibrations
cannot be observed in the complexed system, and no useful
information is acquired in the far IR region.
Here we put forward a new idea that by using
INS further insight on the local dynamics of the pure
drug molecule and how its dynamics is affected by the
encapsulation can be obtained. Since neutron scattering is
not a surface technique and the sample does not need to
be manipulated in order to obtain the data, this probe is
extremely suitable for confinement studies. Additionally,
we presented results following the classical approach to
confirm that PTX was encapsulated into the bio-NCP.
Our results, even if in a very early stage, are
encouraging. Using neutron scattering we show that a
number of vibrational modes are damped indicating that
the PTX molecule is constrained by the encapsulation.
Moreover from the analysis of the QENS data we were
able to obtain valuable information on the flexiblility of the
PTX molecular groups, and how this flexibility might be
modified by encapsulation in the drug carrier bio-NCP +
PTX. Further analyses are under way and will be discussed
in a future publication.
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